Bionyra's $165M Launch
Bionyra Pharma Emerges With $165M Series A to Tackle Immune-Mediated Inflammatory Diseases
Anonymous
Key Points
1
Beyond the Series A co-leads (Jeito Capital and Sofinnova Partners), the round also included investors Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures.
2
CEO and co-founder Dr. Frédéric Marrache said the need is large and that current approaches fall short: “More than half of patients suffering from immune-mediated inflammatory diseases remain inadequately controlled,” and Bionyra is “selectively modulating immune pathways… where current therapies remain insufficient.”
3
Marrache described BYN-003’s differentiation, calling it “the only bispecific molecule for these kinds of diseases” that “already has some level of clinical validation for one of its building blocks.”
4
For BYN-001 (anti-IL-25), Bionyra is planning a dosing concept aimed at convenience and combination potential—Marrache said the company is targeting a “quarterly or twice-yearly injection,” which he said “sets up very well” for combination with approved therapies.
5
Sofinnova’s role in identifying opportunities included proprietary technology: Marrache said Sofinnova has a “global map” of innovation that is “updated weekly,” which led to Bionyra reviewing “more than 100 opportunities.”
Paris-based Bionyra Pharma launched from stealth on June 22 with a $165 million Series A — the largest such round ever raised by a French biotech, according to Business Wire. The oversubscribed round was co-led by Jeito Capital and Sofinnova Partners, with Sanofi Ventures, Arkin Bio, Apollo Health Ventures, Sixty Degree Capital, and Vives Partners also joining.
CEO and co-founder Dr. Frédéric Marrache, a former Sanofi immunology executive, is building a pipeline of antibodies targeting inflammatory diseases like atopic dermatitis and inflammatory bowel disease (IBD). He says the need is urgent: "More than half of patients suffering from immune-mediated inflammatory diseases remain inadequately controlled," BioSpace reported.
Three Drugs Target Pathways That Current Therapies Miss
Bionyra's lead drug, BYN-002, is a monoclonal antibody targeting TL1A — a protein linked to gut and skin inflammation. Its Phase 1 study in healthy subjects is now fully enrolled, according to Pulse 2.0. The drug uses half-life extension (HLE) technology, meaning it stays active in the body longer so patients need fewer injections.
BYN-003 entered the clinic in April 2026. It is a bispecific antibody — a drug that blocks two immune signals at once, TL1A and IL-23p19. Marrache called it "the only bispecific molecule for these kinds of diseases" that "already has some level of clinical validation for one of its building blocks," BioPharma Dive reported. A third drug, BYN-001, targets IL-25 for atopic dermatitis and is still in pre-trial development.
Bionyra Eyes Quarterly Shots to Outlast Dupixent
One of Bionyra's biggest bets is dosing convenience. For BYN-001, the atopic dermatitis drug, Marrache is targeting a "quarterly or twice-yearly injection," according to BioPharma Dive. That would be a major step up from Dupixent, the current standard of care, which patients inject every two weeks. Fewer injections could drive better real-world adherence.
All three assets were licensed from two companies: TrueLab Biopharmaceutical and NovaRock Biotherapeutics. Bionyra holds exclusive global rights outside of Greater China. TrueLab's deal alone carries potential milestone payments totaling up to $985 million, according to PR Newswire. TrueLab also received a small equity stake — described as single-digit — in Bionyra.
Bionyra Joins a TL1A Race Worth Tens of Billions
The TL1A space has attracted massive bets from big pharma. Merck paid $10.8 billion to acquire Prometheus Biosciences in 2023, according to The Pharmaletter. Roche spent $7.1 billion to buy Telavant for its TL1A drug. Sanofi and Teva are already running Phase 3 trials on their TL1A candidate, duvakitug. Bionyra is entering a field where the leaders have multi-year head starts.
Supporters frame Bionyra as the next evolution of the class, not a latecomer. Jeito Capital partner Mehdi Ainouche said, "You're clearly on the next generation of biologics... we will try to beat the efficacy ceiling," according to BioPharma Dive. Bionyra plans to deliver proof-of-concept patient data across all three programs by late 2028, Endpoints News reported.
Sofinnova's Global Innovation Map Led to 100-Plus Reviews
Sofinnova Partners co-founded Bionyra after running a systematic search. Marrache said Sofinnova maintains a "global map" of innovation that is "updated weekly," which led the team to review "more than 100 opportunities" before selecting its three assets, according to EU Startups. Sofinnova provided seed funding before co-leading the Series A alongside Jeito Capital.
The assets came from Chinese biotechs TrueLab and NovaRock — part of a broader trend of Western companies licensing innovation out of China. Sofinnova Chairman Antoine Papiernik noted the model itself is decades old, but said China has emerged as a "prolific creator" driving it today, according to Endpoints News. For France, the €143 million raise marks a new high-water mark for early-stage biotech funding in the country.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
11
Reach
24
A
AnonymousAuthor
